As of today, FGFR2 presents as a relevant new biomarker with prognostic significance that stands to be integrated into current diagnostic and treatment algorithms, as the advancement of these new treatment modalities may significantly improve outcomes for this subset of patients with aggressive gastric cancer. Here, FGFR2 is linked to gastric cancer.